Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines
Abstract
:1. Introduction
2. Epidemiology
3. Diagnosis & Classification
4. Treatment
4.1. Localized
4.2. Locally Advanced
4.3. Metastatic
4.4. Somatostatin Analogs (SSA)
4.5. Targeted Therapy
4.6. Cytotoxic Chemotherapy
5. Peptide Receptor Radionucleotide Therapy (PRRT)
6. Future Advancements
7. Conclusions
Funding
Conflicts of Interest
References
- Yao, J.C.; Hassan, M.; Phan, A.; Dagohoy, C.; Leary, C.; Mares, J.E.; Abdalla, E.K.; Fleming, J.B.; Vauthey, J.N.; Rashid, A.; et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008, 26, 3063–3072. [Google Scholar] [CrossRef] [PubMed]
- Travis, W.D. Advances in neuroendocrine lung tumors. Ann. Oncol. 2010, 21, vii65–vii71. [Google Scholar] [CrossRef] [PubMed]
- Travis, W.D.; Brambilla, E.; Muller-Hermelink, H.K.; Harris, C.C. Pathology and genetics of tumours of the lung. Bull. World Health Organ. 2004, 50, 9–19. [Google Scholar]
- Ferguson, M.K.; Landreneau, R.J.; Hazelrigg, S.R.; Altorki, N.K.; Naunheim, K.S.; Zwischenberger, J.B.; Kent, M.; Yim, A.P.C. Long-term outcome after resection for bronchial carcinoid tumors. Eur. J. Cardio-Thorac. Surg. 2000, 18, 156–161. [Google Scholar] [CrossRef]
- Gustafsson, B.I.; Kidd, M.; Chan, A.; Malfertheiner M, V.; Modlin, I.M. Bronchopulmonary neuroendocrine tumors. Cancer 2008, 113, 5–21. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Filosso, P.L.; Oliaro, A.; Ruffini, E.; Bora, G.; Lyberis, P.; Asioli, S.; Delsedime, L.; Sandri, A.; Guerrera, F. Outcome and prognostic factors in bronchial carcinoids: A single-center experience. J. Thorac. Oncol. 2013, 8, 1282–1288. [Google Scholar] [CrossRef] [PubMed]
- Skuladottir, H.; Hirsch, F.R.; Hansen, H.H.; Olsen, J.H. Pulmonary neuroendocrine tumors: Incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002, 37, 127–135. [Google Scholar] [CrossRef]
- Cardillo, G.; Sera, F.; Di Martino, M.; Graziano, P.; Giunti, R.; Carbone, L.; Facciolo, F.; Martelli, M. Bronchial carcinoid tumors: Nodal status and long-term survival after resection. Ann. Thorac. Surg. 2004, 77, 1781–1785. [Google Scholar] [CrossRef] [PubMed]
- Asamura, H.; Kameya, T.; Matsuno, Y.; Noguchi, M.; Tada, H.; Ishikawa, Y.; Yokose, T.; Jiang, S.X.; Inoue, T.; Nakagawa, K.; et al. Neuroendocrine neoplasms of the lung: A prognostic spectrum. J. Clin. Oncol. 2006, 24, 70–76. [Google Scholar] [CrossRef]
- Sculier, J.P.; Chansky, K.; Crowley, J.J.; Van Meerbeeck, J.; Goldstraw, P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition. J. Thorac. Oncol. 2008, 3, 457–466. [Google Scholar] [CrossRef]
- Rekhtman, N. Neuroendocrine Tumors of the Lung—An Update. Arch. Pathol. Lab. Med. 2010, 134, 1628–1638. [Google Scholar]
- Phan, A.T.; Oberg, K.; Choi, J.; Harrison, L.H.; Hassan, M.M.; Strosberg, J.R.; Krenning, E.P.; Kocha, W.; Woltering, E.A.; Maples, W.J. NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus). Pancreas 2010, 39, 784–798. [Google Scholar] [CrossRef] [PubMed]
- Oliveira, A.M.; Tazelaar, H.D.; Wentzlaff, K.A.; Kosugi, N.S.; Hai, N.; Benson, A.; Miller, D.L.; Yang, P. Familial pulmonary carcinoid tumors. Cancer 2001, 10, 697–704. [Google Scholar] [CrossRef]
- Modlin, I.M.; Lye, K.D.; Kidd, M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003, 97, 934–959. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Caplin, M.E.; Baudin, E.; Ferolla, P.; Filosso, P.; Garcia-Yuste, M.; Lim, E.; Oberg, K.; Pelosi, G.; Perren, A.; Rossi, R.E.; et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann. Oncol. 2015, 26, 1604–1620. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hemminki, K.; Li, X. Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer 2001, 92, 2204–2210. [Google Scholar] [CrossRef]
- de Jong, W.K.; Schaapveld, M.; Blaauwgeers, J.L.G.; Groen, H.J.M. Pulmonary tumours in the Netherlands: Focus on temporal trends in histology and stage and on rare tumours. Thorax 2008, 63, 1096–1102. [Google Scholar] [CrossRef]
- Hauso, O.; Gustafsson, B.I.; Kidd, M.; Waldum, H.L.; Drozdov, I.; Chan, A.K.C.; Modlin, I.M. Neuroendocrine tumor epidemiology: Contrasting Norway and North America. Cancer 2008, 113, 2655–2664. [Google Scholar] [CrossRef]
- Faggiano, A.; Ferolla, P.; Grimaldi, F.; Campana, D.; Manzoni, M.; Davì, M.V.; Bianchi, A.; Valcavi, R.; Papini, E.; Giuffrida, D.; et al. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data froma large prospective and retrospective Italian Epidemiological study: The net management study. J. Endocrinol. Investig. 2012, 35, 817–823. [Google Scholar]
- Zuetenhorst, J.M.; Taal, B.G. Metastatic carcinoid tumors: A clinical review.1. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: A clinical review. Oncologist 2005, 10, 123–131. [Google Scholar] [CrossRef]
- Filosso, P.L.; Rena, O.; Donati, G.; Casadio, C.; Ruffini, E.; Papalia, E.; Oliaro, A.; Maggi, G. Bronchial carcinoid tumors: Surgical management and long-term outcome. J. Thorac. Cardiovasc. Surg. 2002, 123, 303–309. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hassan, M.M.; Phan, A.; Li, D.; Dagohoy, C.G.; Leary, C.; Yao, J.C. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int. J. Cancer 2008, 123, 867–873. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hendifar, A.E.; Marchevsky, A.M.; Tuli, R. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease. J. Thorac. Oncol. 2017, 12, 425–436. [Google Scholar] [CrossRef] [PubMed]
- Öberg, K.; Hellman, P.; Ferolla, P.; Papotti, M. Neuroendocrine bronchial and thymic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012, 23, vii120–vii123. [Google Scholar] [PubMed]
- Halperin, D.M.; Shen, C.; Dasari, A.; Xu, Y.; Chu, Y.; Zhou, S.; Shih, Y.C.T.; Yao, J.C. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: A population-based study. Lancet Oncol. 2017, 18, 525–534. [Google Scholar] [CrossRef]
- Ejaz, S.; Vassilopoulou-Sellin, R.; Busaidy, N.L.; Hu, M.I.; Waguespack, S.G.; Jimenez, C.; Ying, A.K.; Cabanillas, M.; Abbara, M.; Habra, M.A. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: The University of Texas MD Anderson Cancer Center Experience. Cancer 2011, 117, 4381–4389. [Google Scholar] [CrossRef] [PubMed]
- Limper, A.H.; Carpenter, P.C.; Scheithauer, B.; Staats, B.A. The Cushing syndrome induced by bronchial carcinoid tumors. Ann. Intern. Med. 1992, 117, 209–214. [Google Scholar] [CrossRef]
- Morandi, U.; Casali, C.; Rossi, G. Bronchial Typical Carcinoid Tumors. Semin. Thorac. Cardiovasc. Surg. 2006, 18, 191–198. [Google Scholar] [CrossRef]
- Fainstein Day, P.; Frohman, L.; Rivello, H.G.; Reubi, J.C.; Sevlever, G.; Glerean, M.; Gianotti, T.F.; Pietrani, M.; Rabadan, A.; Racioppi, S.; et al. Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: A case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment. Pituitary 2007, 10, 311–319. [Google Scholar] [CrossRef]
- Chong, C.R.; Wirth, L.J.; Nishino, M.; Chen, A.B.; Sholl, L.M.; Kulke, M.H.; McNamee, C.J.; Jänne, P.A.; Johnson, B.E. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer 2014, 86, 241–246. [Google Scholar] [CrossRef] [Green Version]
- Travis, W.D.; Brambilla, E.; Burke, A.P.; Marx, A.; Nicholson, A.G. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed.; IARC Publications: Lyon, France, 2015. [Google Scholar]
- Travis, W.D. Pathology and Diagnosis of Neuroendocrine Tumors: Lung Neuroendocrine. Thorac. Surg. Clin. 2014, 24, 257–266. [Google Scholar] [CrossRef] [PubMed]
- Travis, W.D.; Gal, A.A.; Colby T, V.; Klimstra, D.S.; Falk, R.; Koss, M.N. Reproducibility of neuroendocrine lung tumor classification. Hum. Pathol. 1998, 29, 272–279. [Google Scholar] [CrossRef]
- Pelosi, G.; Rodriguez, J.; Viale, G.; Rosai, J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: A major pitfall in the management of lung cancer patients. Am. J. Surg. Pathol. 2005, 29, 179–187. [Google Scholar] [CrossRef] [PubMed]
- Travis, W.D.; Brambilla, E.; Müller-hermelink, H.K.; Harris, C.C. Pathology & Genetics Tumours of the Lung, Pleura, Thymus and Heart; World Health Organization Classification of Tumours; IARC/Press: Lyon, France, 2004; pp. 9–122. [Google Scholar]
- Walts, A.E.; Ines, D.; Marchevsky, A.M. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod. Pathol. 2012, 29, 1258. [Google Scholar] [CrossRef] [PubMed]
- Öberg, K.; Sundin, A. Imaging of Neuroendocrine Tumors. Front. Horm. Res. 2016, 45, 142–151. [Google Scholar] [PubMed]
- Mojtahedi, A.; Thamake, S.; Tworowska, I.; Ranganathan, D.; Delpassand, E.S. The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: A review of literature. Am. J. Nucl. Med. Mol. Imaging 2014, 4, 426. [Google Scholar] [PubMed]
- Reubi, J.C.; Schär, J.-C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J.S.; Mäcke, H.R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. Mol. Imaging 2000, 27, 273–282. [Google Scholar] [CrossRef]
- Haug, A.R.; Cindea-Drimus, R.; Auernhammer, C.J.; Reincke, M.; Wangler, B.; Uebleis, C.; Schmidt, G.P.; Goke, B.; Bartenstein, P.; Hacker, M. The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors. J. Nucl. Med. 2012, 53, 1686–1692. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Haug, A.R.; Cindea-Drimus, R.; Auernhammer, C.J.; Reincke, M.; Beuschlein, F.; Wängler, B.; Uebleis, C.; Schmidt, G.P.; Spitzweg, C.; Bartenstein, P.; Hacker, M. Neuroendocrine Tumor Recurrence: Diagnosis with 68Ga-DOTATATE PET/CT. Radiology 2014, 270, 517–525. [Google Scholar] [CrossRef] [PubMed]
- Srirajaskanthan, R.; Kayani, I.; Quigley, A.M.; Soh, J.; Caplin, M.E.; Bomanji, J. The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy. J. Nucl. Med. 2010, 51, 875. [Google Scholar] [CrossRef] [PubMed]
- Krausz, Y.; Freedman, N.; Rubinstein, R.; Lavie, E.; Orevi, M.; Tshori, S.; Salmon, A.; Glaser, B.; Chisin, R.; Mishani, E.; et al. 68Ga-DOTA-NOC PET/CT Imaging of Neuroendocrine Tumors: Comparison with 111In-DTPA-Octreotide (OctreoScan®). Mol. Imaging Biol. 2011, 13, 583–593. [Google Scholar] [CrossRef] [PubMed]
- Yellin, A.; Zwas, S.T.; Rozenman, J.; Simansky, D.A.; Goshen, E. Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. Isr. Med. Assoc. J. 2005, 7, 712. [Google Scholar] [PubMed]
- Hörsch, D.; Schmid, K.W.; Anlauf, M.; Darwiche, K.; Denecke, T.; Baum, R.P.; Spitzweg, C.; Grohé, C.; Presselt, N.; Stremmel, C.; et al. Neuroendocrine tumors of the bronchopulmonary system (Typical and Atypical Carcinoid Tumors): Current Strategies in Diagnosis and Treatment. Conclusions of an Expert Meeting February 2011 in Weimar, Germany. Oncol. Res. Treat. 2014, 37, 266–276. [Google Scholar] [CrossRef] [PubMed]
- Kunz, P.L.; Reidy-Lagunes, D.; Anthony, L.B.; Bertino, E.M.; Brendtro, K.; Chan, J.A.; Chen, H.; Jensen, R.T.; Kim, M.K.; Klimstra, D.S.; et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013, 42, 557. [Google Scholar] [CrossRef] [PubMed]
- National Comprehensive Cancer Network. 2017 NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors. Version 3; NCCN: Plymouth Meeting, PA, USA, 2017. [Google Scholar]
- Rea, F.; Rizzardi, G.; Zuin, A.; Marulli, G.; Nicotra, S.; Bulf, R.; Schiavon, M.; Sartori, F. Outcome and surgical strategy in bronchial carcinoid tumors: Single institution experience with 252 patients. Eur. J. Cardio-Thorac. Surg. 2007, 31, 186–191. [Google Scholar] [CrossRef] [PubMed]
- Detterbeck, F.C. Management of Carcinoid Tumors. Ann. Thorac. Surg. 2010, 89, 998–1005. [Google Scholar] [CrossRef]
- Filosso, P.L.; Guerrera, F.; Evangelista, A.; Welter, S.; Thomas, P.; Casado, P.M.; Rendina, E.A.; Venuta, F.; Ampollini, L.; Brunelli, A.; et al. Prognostic model of survival for typical bronchial carcinoid tumours: Analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group. Eur. J. Cardio-Thorac. Surg. 2015, 48, 441–447. [Google Scholar] [CrossRef]
- Steuer, C.E.; Behera, M.; Kim, S.; Chen, Z.; Saba, N.F.; Pillai, R.N.; Owonikoko, T.K.; Khuri, F.R.; Ramalingam, S.S. Atypical carcinoid tumor of the lung: A surveillance, epidemiology, and end results database analysis. J. Thorac. Oncol. 2015, 10, 479–485. [Google Scholar] [CrossRef]
- Ducrocq, X.; Thomas, P.; Massard, G.; Barsotti, P.; Giudicelli, R.; Fuentes, P.; Wihlm, J.M. Operative risk and prognostic factors of typical bronchial carcinoid tumors. Ann. Thorac. Surg. 1998, 65, 1410–1414. [Google Scholar] [CrossRef]
- Afoke, J.; Tan, C.; Hunt, I.; Zakkar, M. Is sublobar resection equivalent to lobectomy for surgical management of peripheral carcinoid? Interact. Cardiovasc. Thorac. Surg. 2013, 16, 858–863. [Google Scholar] [CrossRef] [Green Version]
- Bölükbas, S.; Schirren, J. Parenchyma-sparing bronchial sleeve resections in trauma, benign and malign diseases. Thorac. Cardiovasc. Surg. 2010, 58, 32–37. [Google Scholar] [CrossRef] [PubMed]
- Fox, M.; Van Berkel, V.; Bousamra, M.; Sloan, S.; Martin, R.C.G. Surgical management of pulmonary carcinoid tumors: Sublobar resection versus lobectomy. Am. J. Surg. 2013, 205, 200–208. [Google Scholar] [CrossRef] [PubMed]
- Yendamuri, S.; Gold, D.; Jayaprakash, V.; Dexter, E.; Nwogu, C.; Demmy, T. Is sublobar resection sufficient for carcinoid tumors? Ann. Thorac. Surg. 2011, 92, 1774–1779. [Google Scholar] [CrossRef] [PubMed]
- Pavel, M.; O’Toole, D.; Costa, F.; Capdevila, J.; Gross, D.; Kianmanesh, R.; Krenning, E.; Knigge, U.; Salazar, R.; Pape, U.F.; Öberg, K. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016, 103, 172–185. [Google Scholar] [CrossRef] [PubMed]
- Nussbaum, D.P.; Speicher, P.J.; Gulack, B.C.; Hartwig, M.G.; Onaitis, M.W.; D’Amico, T.A.; Berry, M.F. Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors. Ann. Thorac. Surg. 2015, 99, 428–434. [Google Scholar] [CrossRef] [PubMed]
- Anderson, K.L.; Mulvihill, M.S.; Speicher, P.J.; Yerokun, B.A.; Gulack, B.C.; Nussbaum, D.P.; Harpole, D.H.; D’Amico, T.A.; Berry, M.F.; Hartwig, M.G. Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors. Ann. Thorac. Surg. 2017, 104, 1221–1230. [Google Scholar] [CrossRef] [PubMed]
- Westin, G.F.M.; Alsidawi, S.; Leventakos, K.; Halfdanarson, T.R.; Molina, J.R. Impact of adjuvant chemotherapy in non-metastatic node positive bronchial neuroendocrine tumors (BNET). J. Clin. Oncol. 2017, 35, 8533. [Google Scholar] [CrossRef]
- Wirth, L.J.; Carter, M.R.; Jänne, P.A.; Johnson, B.E. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 2004, 44, 213–220. [Google Scholar] [CrossRef] [PubMed]
- Faiss, S.; Pape, U.F.; Böhmig, M.; Dörffel, Y.; Mansmann, U.; Golder, W.; Riecken, E.O.; Wiedenmann, B. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—The International Lanreotide and Interferon Alfa Stud. J. Clin. Oncol. 2003, 21, 2689–2696. [Google Scholar] [CrossRef] [PubMed]
- Aparicio, T.; Ducreux, M.; Baudin, E.; Sabourin, J.C.; De Baere, T.; Mitry, E.; Schlumberger, M.; Rougier, P. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur. J. Cancer 2001, 37, 1014–1019. [Google Scholar] [CrossRef]
- Ducreux, M.; Ruszniewski, P.; Chayvialle, J.A.; Blumberg, J.; Cloarec, D.; Michel, H.; Raymond, J.M.; Dupas, J.L.; Gouerou, H.; Jian, R.; et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am. J. Gastroenterol. 2000, 95, 3276–3281. [Google Scholar] [CrossRef] [PubMed]
- Sullivan, I.; Le Teuff, G.; Guigay, J.; Caramella, C.; Berdelou, A.; Leboulleux, S.; Déandréis, D.; Hadoux, J.; Ducreux, M.; Duvillard, P.; et al. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. Eur. J. Cancer 2017, 75, 259–267. [Google Scholar] [CrossRef] [PubMed]
- Rinke, A.; Müller, H.H.; Schade-Brittinger, C.; Klose, K.J.; Barth, P.; Wied, M.; Mayer, C.; Aminossadati, B.; Pape, U.F.; Bläker, M.; et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J. Clin. Oncol. 2009, 27, 4656–4663. [Google Scholar] [CrossRef] [PubMed]
- Caplin, M.E.; Pavel, M.; Ćwikła, J.B.; Phan, A.T.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Wolin, E.M.; Capdevila, J.; Wall, L.; et al. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. N. Engl. J. Med. 2014, 371, 224–233. [Google Scholar] [CrossRef] [PubMed]
- Reidy-Lagunes, D.; Kulke, M.; Wolin, E.; Singh, S.; Ferone, D.; Mirakhur, B.; Hoffmanns, P.; Houchard, A.; Caplin, M.; Baudin, E. SPINET: A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Lanreotide Autogel/Depot (LAN) in Patients with Advanced Lung Neuroendocrine Tumors. Pancreas 2017, 46, 451. [Google Scholar]
- Pavel, M.E.; Hainsworth, J.D.; Baudin, E.; Peeters, M.; Hörsch, D.; Winkler, R.E.; Klimovsky, J.; Lebwohl, D.; Jehl, V.; Wolin, E.M.; et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 2011, 378, 2005–2012. [Google Scholar] [CrossRef]
- Yao, J.C.; Phan, A.T.; Chang, D.Z.; Wolff, R.A.; Hess, K.; Gupta, S.; Jacobs, C.; Mares, J.E.; Landgraf, A.N.; Rashid, A.; et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J. Clin. Oncol. 2008, 26, 4311. [Google Scholar] [CrossRef]
- Yao, J.C.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lancet 2016, 387, 968. [Google Scholar] [CrossRef]
- Crona, J.; Fanola, I.; Lindholm, D.P.; Antonodimitrakis, P.; Öberg, K.; Eriksson, B.; Granberg, D. Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology 2013, 98, 151. [Google Scholar] [CrossRef]
- Spada, F.; Fumagalli, C.; Antonuzzo, L.; Al, E. Capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NEN): An Italian multicenter retrospective analysis. J. Clin. Oncol. 2014, 32, 281. [Google Scholar] [CrossRef]
- Forde, P.M.; Hooker, C.M.; Boikos, S.; Petrini, I.; Giaccone, G.; Rudin, C.M.; Yang, S.C.; Illei, P.B.; Hann, C.L.; Ettinger, D.S.; et al. Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid. J. Thorac. Oncol. 2014, 9, 414–418. [Google Scholar] [CrossRef] [PubMed]
- Granberg, D.; Eriksson, B.; Wilander, E.; Grimfjärd, P.; Fjällskog, M.L.; Oberg, K.; Skogseid, B. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann. Oncol. 2001, 12, 1383–1391. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fjällskog, M.L.; Granberg, D.P.; Welin, S.L.; Eriksson, C.; Oberg, K.E.; Janson, E.T.; Eriksson, B.K. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001, 92, 1101–1107. [Google Scholar] [CrossRef] [Green Version]
- Ekeblad, S.; Sundin, A.; Janson, E.T.; Welin, S.; Granberg, D.; Kindmark, H.; Dunder, K.; Kozlovacki, G.; Orlefors, H.; Sigurd, M.; et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res. 2007, 13, 2986–2991. [Google Scholar] [CrossRef] [PubMed]
- Fine, R.L.; Gulati, A.P.; Krantz, B.A.; Moss, R.A.; Schreibman, S.; Tsushima, D.A.; Mowatt, K.B.; Dinnen, R.D.; Mao, Y.; Stevens, P.D.; et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother. Pharmacol. 2013, 71, 663–670. [Google Scholar] [CrossRef] [PubMed]
- Chan, J.A.; Stuart, K.; Earle, C.C.; Clark, J.W.; Bhargava, P.; Miksad, R.; Blaszkowsky, L.; Enzinger, P.C.; Meyerhardt, J.A.; Zheng, H.; et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2012, 30, 2963. [Google Scholar] [CrossRef]
- Kulke, M.H.; Stuart, K.; Enzinger, P.C.; Ryan, D.P.; Clark, J.W.; Muzikansky, A.; Vincitore, M.; Michelini, A.; Fuchs, C.S. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol. 2006, 24, 401–406. [Google Scholar] [CrossRef]
- Kwekkeboom, D.J.; Bakker, W.H.; Kam, B.L.; Teunissen, J.J.M.; Kooij, P.P.M.; Herder, W.W.; Feelders, R.A.; Eijck, C.H.J.; Jong, M.; Srinivasan, A.; et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 417–422. [Google Scholar] [CrossRef]
- Kwekkeboom, D.J.; de Herder, W.W.; Kam, B.L.; van Eijck, C.H.; van Essen, M.; Kooij, P.P.; Feelders, R.A.; van Aken, M.O.; Krenning, E.P. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: Toxicity, efficacy, and survival. J. Clin. Oncol. 2008, 26, 2124–2130. [Google Scholar] [CrossRef]
- Van Essen, M.; Krenning, E.P.; Kam, B.L.R.; De Jong, M.; Valkema, R.; Kwekkeboom, D.J. Peptide-receptor radionuclide therapy for endocrine tumors. Nat. Rev. Endocrinol. 2009, 5, 382. [Google Scholar] [CrossRef]
- Strosberg, J.; El-Haddad, G.; Wolin, E.; Hendifar, A.; Yao, J.; Chasen, B.; Mittra, E.; Kunz, P.L.; Kulke, M.H.; Jacene, H.; et al. Krenning for the N-1 T I Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N. Engl. J. Med. 2017, 376, 125–135. [Google Scholar] [CrossRef] [PubMed]
- Reubi, J.C.; Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 781–793. [Google Scholar] [CrossRef] [PubMed]
- Parghane, R.V.; Talole, S.; Prabhash, K.; Basu, S. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Clin. Nucl. Med. 2017, 42, 428–435. [Google Scholar] [CrossRef] [PubMed]
- Mariniello, A.; Bodei, L.; Tinelli, C.; Baio, S.M.; Gilardi, L.; Colandrea, M.; Papi, S.; Valmadre, G.; Fazio, N.; Galetta, D.; et al. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 441–452. [Google Scholar] [CrossRef] [PubMed]
- Brabander, T.; Van Der Zwan, W.A.; Teunissen, J.J.M.; Kam, B.L.R.; Feelders, R.A.; De Herder, W.W.; Van Eijck, C.H.J.; Franssen, G.J.H.; Krenning, E.P.; Kwekkeboom, D.J. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin. Cancer Res. 2017, 2017, 2743. [Google Scholar] [CrossRef] [PubMed]
- Sharma, N.; Naraev, B.G.; Engelman, E.G.; Zimmerman, M.B.; Bushnell, D.L.; O’Dorisio, T.M.; O’Dorisio, M.S.; Menda, Y.; Müller-Brand, J.; Howe, J.R.; et al. Peptide receptor radionuclide therapy outcomes in a North American cohort with metastatic well-differentiated neuroendocrine tumors. Pancreas 2017, 46, 151. [Google Scholar] [CrossRef] [PubMed]
- Khan, S.; Krenning, E.P.; van Essen, M.; Kam, B.L.; Teunissen, J.J.; Kwekkeboom, D.J. Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate. J. Nucl. Med. 2011, 52, 1361. [Google Scholar] [CrossRef]
- Lo Russo, G.; Pusceddu, S.; Prinzi, N.; Imbimbo, M.; Proto, C.; Signorelli, D.; Vitali, M.; Ganzinelli, M.; Maccauro, M.; Buzzoni, R.; et al. Peptide receptor radionuclide therapy: Focus on bronchial neuroendocrine tumors. Tumor Biol. 2016, 37, 12991. [Google Scholar] [CrossRef]
- Christofori, G.; Naik, P.; Hanahan, D. Vascular Endothelial Growth-Factor and Its Receptors, Flt-1 and Flk-1, Are Expressed in Normal Pancreatic-Islets and Throughout Islet-Cell Tumorigenesis. Mol. Endocrinol. 1995, 9, 1760. [Google Scholar]
- La Rosa, S.; Uccella, S.; Finzi, G.; Albarello, L.; Sessa, F.; Capella, C. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: Correlation with microvessel density and clinicopathologic. Hum. Pathol. 2003, 34, 18–27. [Google Scholar] [CrossRef]
- Terris, B.; Scoazec, J.Y.; Rubbia, L.; Bregeaud, L.; Pepper, M.S.; Ruszniewski, P.; Belghiti, J.; Fléjou, J.F.; Degott, C. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998, 32, 133–138. [Google Scholar] [CrossRef] [PubMed]
- Couvelard, A.; O’Toole, D.; Turley, H.; Leek, R.; Sauvanet, A.; Degott, C.; Ruszniewski, P.; Belghiti, J.; Harris, A.L.; Gatter, K.; et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: Negative correlation of microvascular density and VEGF expression with tumour progression. Br. J. Cancer 2005, 92, 94. [Google Scholar] [CrossRef] [PubMed]
- Raymond, E.; Dahan, L.; Raoul, J.L.; Bang, Y.J.; Borbath, I.; Lombard-Bohas, C. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N. Engl. J. Med. 2011, 364, 501–513. [Google Scholar] [CrossRef] [PubMed]
- Azzoni, C.; Bottarelli, L.; Cecchini, S.; Lagrasta, C.; Pizzi, S.; D’Adda, T.; Tamburini, E.; Rindi, G.; Bordi, C. Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors. Virchows Arch. 2011, 458, 525–536. [Google Scholar] [CrossRef] [PubMed]
- Chan, J.; Faris, J.; Murphy, J.; Blaszkowsky, L.; Kwak, E.; McCleary, N.; Fuchs, C.; Meyerhardt, J.; Ng, K.; Zhu, A.; et al. Phase II trial of cabozantinib in patientswith carcinoid and pancreatic neuroendocrine tumors. Pancreas 2018, 47, 334. [Google Scholar]
- Iyer, R.; Konda, B.; Owen, D.; Attwood, K.; Sarker, S.; Suffren, S.; Wilton, J.; Bies, R.; Casucci, D.; Reidy, D.; et al. Multicenter phase 2 study of nintedanib in patients (pts) with advanced progressing carcinoid tumors. J. Clin. Oncol. 2018, 36, 4105. [Google Scholar] [CrossRef]
- Antonia, S.J.; López-Martin, J.A.; Bendell, J.; Ott, P.A.; Taylor, M.; Eder, J.P.; Jäger, D.; Pietanza, M.C.; Le, D.T.; de Braud, F.; et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016, 26, 3063–3072. [Google Scholar] [CrossRef]
- Crabtree, J.S. Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy. Front. Endocrinol. 2017, 8, 341. [Google Scholar] [CrossRef]
Guidelines | NCCN | NANETS | ENETS | ESMO |
---|---|---|---|---|
Surgical Approach | Lobectomy along with mediastinal node dissection or sampling | Bronchial NETS—Sleeve resection, along with lymph node sampling in well-differentiatedd bronchial NETs Thymic NETS—median sternotomy approach with complete tumor resection and mediastinal lymphadenectomy | Lobectomy/Segmentectomy along with a minimum of 6 lymph nodes sampling, min of three to be mediastinal including subcarinal Central airway tumor—lung parenchymal sparing surgery Bronchial sleeve resection or sleeve lobectomy preferred over pneumonectomy Systemic nodal dissection | Inoperable—Bronchoscopic laser excision of intraluminal typical bronchial NETs Lobectomy/sleeve resection, along with systemic nodal dissection |
Adjuvant Regimen | Stage IIIA/B ACs radiation +/− chemotherapy | No recommendations | Consider adjuvant therapy in ACs with positive lymph nodes | No recommendations |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gosain, R.; Mukherjee, S.; Yendamuri, S.S.; Iyer, R. Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. Cancers 2018, 10, 510. https://doi.org/10.3390/cancers10120510
Gosain R, Mukherjee S, Yendamuri SS, Iyer R. Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. Cancers. 2018; 10(12):510. https://doi.org/10.3390/cancers10120510
Chicago/Turabian StyleGosain, Rohit, Sarbajit Mukherjee, Sai S. Yendamuri, and Renuka Iyer. 2018. "Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines" Cancers 10, no. 12: 510. https://doi.org/10.3390/cancers10120510
APA StyleGosain, R., Mukherjee, S., Yendamuri, S. S., & Iyer, R. (2018). Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. Cancers, 10(12), 510. https://doi.org/10.3390/cancers10120510